Latest News and Press Releases

Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for...

Phase 2 trial of RTX for OA pain to proceed following FDA clearance.Phase 1b data demonstrated RTX safety for a single intra-articular administration without dose limiting toxicity (DLT) at any doses...

Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled.No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months...

Seventeen subjects with advanced cancer pain received epidural RTX (0.4 to 25 mcg).No dose limiting toxicities were reported.A majority of patients reported meaningful pain reduction of 30% or more...

Fourteen subjects with advanced cancer pain received epidural RTX (04 to 15 ug)Most common treatment-related adverse event was transient post-procedure related painThree subjects at the higher doses...

Phase 1b/2 OA Knee Pain study completed enrollment of 93 patients, with no dose limiting toxicities observed and significant efficacy signal confirmed in expansion cohorts. The program is expected to...

SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in multiple investment...

Forty five patients were treated with escalating doses of RTX in the Phase 1b trial to date. Thirty seven patients received RTX and eight patients received saline (pooled as placebo group).Most...

SAN DIEGO, June 10, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that review of early results from an on-going “declawed cat pain trial” (run by its Ark...

SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin...